Abstract
Heart failure, a growing public health problem worldwide, is a leading cause of morbidity and mortality in industrialized countries. Despite a widely varying and diverse etiology and pathophysiology of heart failure, increased neurohormonal and autonomic nervous system activities and maladaptive cardiac remodeling play crucial roles in the progression of most forms of heart failure. Recent evidence suggests that increased oxidative stress, associated with excessive generation of highly reactive free radicals and an endogenous antioxidants deficit, plays an etiopathological role in the development of heart failure. There is a growing body of evidence to support the beneficial effects of flavonoid-rich dietary supplements on heart failure. These cardioprotective effects might be mediated through several different mechanisms including antioxidant and free-radical scavenging activities, neurohormonal modulation, immunomodulation, antiremodeling activity, and improving the associated coronary risk factors, such as hypertension, dyslipidemia, and diabetes. However, further research needs to be undertaken to understand the exact underlying mechanisms, and to confirm the efficacy and safety of flavonoid-rich dietary supplements.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American Heart Association. Heart Disease and Stroke Statistics-2006 Update. Dallas, TX, American Heart Association, 2006.
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2005;46:1116–1143.
Ferrara R, Mastrorilli F, Pasanisi G, et al. Neurohormonal modulation in chronic heart failure. Eur Heart J 2002;4(Suppl D):D3–D11.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569–582.
Krstevska M, Dzhekova-Stojkova S, Bosilkova G. Menopause, coronary artery disease and antioxidants. Clin Chem Lab Med 2001;39:641–644.
Lopez FA, Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension 2001;38:1400–1405.
Dhalla AK, Hill M, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506–514.
Bauersachs J, Bouloumié A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999; 100:292–298.
Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352–1356.
Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh S, Niaz MA. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992;304:1015–1019.
de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779–785.
Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002;22:19–34.
Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007–1011.
Hertog MGL, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995;155:381–386.
Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996;312:478–481.
Yochum L, Kushi LH, Meyer K, Folsom AR. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol 1999; 149:943–949.
Fuhrman B, Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 2001;12:41–48.
Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr 2005;81(1 Suppl):292S–297S.
Cook NC, Samman S. Flavonoidschemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 1996;7:66–76.
Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biol and Med 1996;20:933–956.
Bone K. Clinical Applications of Ayurvedic and Chinese Herbs. Warwick, Queensland, Australia. Phytotherapy Press, 1996, pp. 131–133.
Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Boca Raton, FL. CRC Press; 1990:319–320.
Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995;49:191–199.
Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J 1997;49:507–510.
Zhang ZZ, Liang XM, Zhang Q, Lu PZ. Characterization and recognition key components in Astragalus membranaceus (Chinese). Yao Xue Xue Bao 2001;36:523–527.
Zhou ZL, Yu P, Lin D. Study on effect of Astragalus injection in treating congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001;21:747–749.
Zhang JG, Yang N, He H, Wei GH, Gao DS, Wang XL, Wang XZ, Song GY. Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure. Chin J Integr Med 2005;11:187–190.
Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure. Chin Med J (Engl) 1998;111:17–23.
Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 2004;74:1945–1955.
Schroder D, Weiser M, Klein P. Efficacy of a homeopathic Crataegus preparation compared with usual therapy for mild (NYHA II) cardiac insufficiency: result of an observational cohort study. Eur J Heart Fail 2003;5:319–326.
Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442. Forsch Komplementarmed Klass Naturheilkd. 2004; 11(1 Suppl):36–39.
Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003; 114:665–674.
Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003;43:637–642.
Corder R, Warburton RC, Khan NQ, Brown RE, Wood EG, Lees DM. The procyanidin-induced pseudo laminar shear stress response: a new concept for the reversal of endothelial dysfunction. Clin Sci 2004;107:513–517.
Stangl V, Lorenz M, Stangl K. The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res 2006;50:218–228.
Priyadarshi S, Valentine B, Han C, et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney Int 2003;63:1785–1790.
Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158–168.
Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931–934.
Zibadi S, Yu Q, Rohdewald P, Larson DF, Watson RR. Impact of Pycnogenol on cardiac extracellular matrix remodeling induced by L-NAME administration to old mice. Cardiovasc Texicol 2007. In press.
Omoni AO, Aluko RE. Soybean foods and their benefits: potential mechanisms of action. Nutr Rev 2005;63:272–283.
McCue P, Shetty K. Health benefits of soy isoflavonoids and strategies for enhancement: a review. Crit Rev Food Sci Nutr 2004;44:361–367.
Ma SF, Guan SD, Zhu Y. Effect of soybean isoflavones on heart function of rats with adriamycininduced heart failure. Zhong Xi Yi Jie He Xue Bao 2004;2:278–280.
Souzeau E, Belanger S, Picard S, Deschepper CF. Dietary isoflavones during pregnancy and lactation provide cardioprotection to offspring rats in adulthood. Am J Physiol Heart Circ Physiol. 2005;289:H715–H721.
Stauffer BL, Konhilas JP, Luczak ED, Leinwand LA. Soy diet worsens heart disease in mice. J Clin Invest 2006; 116:209–216.
Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21,491–21,494.
Yu Q, Watson RR, Marchalonis JJ, Larson DF. A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol 2005;289:H643–H651.
Howard BV, Kritchevsky D. Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 1997;95:2591–2593. Review.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Zibadi, S., Larson, D.F., Watson, R.R. (2008). Flavonoid-Rich Dietary Supplements’ Influence on Heart Failure. In: De Meester, F., Watson, R.R. (eds) Wild-Type Food in Health Promotion and Disease Prevention. Humana Press. https://doi.org/10.1007/978-1-59745-330-1_29
Download citation
DOI: https://doi.org/10.1007/978-1-59745-330-1_29
Publisher Name: Humana Press
Print ISBN: 978-1-58829-668-9
Online ISBN: 978-1-59745-330-1
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)